Results 71 to 80 of about 1,421 (164)
The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets
British Journal of Pharmacology, Volume 182, Issue S1, Page S1-S23, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +51 more
wiley +1 more source
Function of the Endolysosomal Network in Cholesterol Homeostasis and Metabolic Associated Fatty Liver Disease (MAFLD) [PDF]
, 2021 BACKGROUND: Metabolic associated fatty liver disease (MAFLD), also known as non-alcoholic fatty liver disease, has become the leading cause of chronic liver disease worldwide.
van de Sluis, Bart, Vos, Dyonne Y
core +1 more source
Contact Dermatitis, Volume 93, Issue 4, Page 316-327, October 2025.The carba mix was studied in a human cell model to better understand human patch reactions to the mix. Our results support that the carba mix can give rise to cocktail effect and that patch testing with separate carba mix sensitisers may thus be more appropriate.
Linda Ljungberg Silic +5 more
wiley +1 more source
Pre- and post-natal stress programming : developmental exposure to glucocorticoids causes long-term brain-region specific changes to transcriptome in the precocial Japanese quail [PDF]
, 2016 Funding was provided by a Kelvin Smith PhD Scholarship from the University of Glasgow (VM, PH, JR, and KAS), and Biotechnology and Biological Sciences Research Council David Phillips Research Fellowship (K.A.S.).Exposure to stress during early ...
Herzyk, Pawel +3 more
core +2 more sources
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands
ChemMedChem, Volume 20, Issue 9, May 5, 2025.This study highlights the tetrahydropyrrolo[3,4‐c]pyrazole scaffold as a promising platform for S1R ligands development. Key findings include compound 19’s high S1R affinity (Ki=75 nM), influenced by strategic nitrogen substitutions and reduced steric hindrance.
Giuseppe Cosentino +7 more
wiley +1 more source
, 2023 AbstractThe Sigma 2 receptor (σ2R) was described pharmacologically more than three decades ago, but its molecular identity remained obscure until recently when it was identified as transmembrane protein 97 (TMEM97). We and others have shown that σ2R/TMEM97 ligands alleviate mechanical hypersensitivity in mouse neuropathic pain models with a time course
Muhammad Saad Yousuf +16 more
openaire +2 more sources
BMC Genomics, 2019 Background The comparison of expression QTL (eQTL) maps obtained in different tissues is an essential step to understand how gene expression is genetically regulated in a context-dependent manner.
Rayner González-Prendes +9 more
doaj +1 more source
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 11, Issue 2, April-June 2025.Abstract INTRODUCTION CT1812 (zervimesine) is an orally dosed modulator of the sigma‐2 receptor (S2R) currently in clinical development for the treatment of Alzheimer's disease (AD). CT1812 has been shown in preclinical and early clinical trials to selectively prevent and displace binding of amyloid beta oligomers from their synaptic receptors and has ...
Valentina Di Caro +12 more
wiley +1 more source
Alzheimer's &Dementia, Volume 21, Issue 3, March 2025.Abstract INTRODUCTION Alzheimer's disease (AD) selectively affects certain brain regions, yet the mechanisms of selective vulnerability remain poorly understood. The neuromodulatory subcortical system, which includes nuclei exhibiting a range of vulnerability and resilience to AD‐type degeneration, presents a framework for uncovering these mechanisms ...
Alexander J. Ehrenberg +17 more
wiley +1 more source
Rare dysfunctional complement factor I genetic variants and progression to advanced age-related macular degeneration [PDF]
, 2023 PURPOSE: To evaluate associations between rare dysfunctional DESIGN: Prospective, longitudinal study. PARTICIPANTS: Patients aged 55 to 80 years at baseline identifying as White with non-AAMD in 1 or both eyes at baseline were included.
Atkinson, John +5 more
core +2 more sources